Both Hsc70 overexpression and AUY-922 treatment inhibit tumor growth and promote anti-tumor T cell responses; AUY-922 enhances the anti-tumor effect of aPD-L1 and aCTLA4 treatment, therefore providing an approach for developing future cancer immunotherapy. This evidence concerns the gene HSPA8 and neoplasm.